Recent advances in antiretroviral therapy in HIV infection

Journal of the Indian Medical Association

Volumn 108, Issue 1, 2010, Pages 29-34

  Arora, D R ^a,b   Gautam, Vikas ^a,c   Gill, Paramjeet Singh ^a   Mishra, Neeti ^a  

^a POST GRADUATE INSTITUTE OF MEDICAL SCIENCES   (India)

^b VCTC for AIDS   (India)

^c GOVERNMENT MEDICAL COLLEGE AND HOSPITAL   (India)

Author keywords

Antiretroviral therapy; Human immunodeficiency virus; Viral load

Indexed keywords

ABACAVIR; ALCOHOL; AMPRENAVIR; ANTACID AGENT; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; EMIVIRINE; INDINAVIR; LAMIVUDINE; LOVIRIDE; N [4 CHLORO 3 (3 METHYL 2 BUTENYLOXY)PHENYL] 2 METHYL 3 FURANCARBOTHIOAMIDE; NELFINAVIR; NEVIRAPINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; TALVIRALINE; TIPRANAVIR; VIRUS ENZYME; ZALCITABINE; ZIDOVUDINE; ANTIRETROVIRUS AGENT;

ACUTE PANCREATITIS; DIARRHEA; DISEASE CONTROL; DISEASE COURSE; DISTRESS SYNDROME; DIZZINESS; DRUG BINDING; DRUG MONITORING; GASTROINTESTINAL DISEASE; HEADACHE; HEPATITIS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 2; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOTHERAPY; INSULIN RESISTANCE; LIPID BLOOD LEVEL; LIPODYSTROPHY; MACULOPAPULAR RASH; MUTANT; MYOPATHY; NAUSEA; NEPHROLITHIASIS; NEUROPATHY; NUCLEIC ACID AMPLIFICATION; ORAL PARESTHESIA; PANCREATITIS; PERIPHERAL NEUROPATHY; PLASMA HALF LIFE; RASH; REVIEW; STEVENS JOHNSON SYNDROME; VIRUS LOAD; VIRUS REPLICATION; VOMITING; DRUG COMBINATION; FEMALE; PREGNANCY; PREGNANCY COMPLICATION; TREATMENT OUTCOME;

ANTI-RETROVIRAL AGENTS; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HUMANS; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; PROTEASE INHIBITORS; TREATMENT OUTCOME; VIRAL LOAD;

EID: 77957337427     PISSN: 00195847     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (43)

1. Henry J, Kaiser HJ - Guidelines for the use of antiretroviral agents in HIV infected adults and adolescents. MMWR Morb Mortal Wkly Rep 1988; 47: 43-82.
2. Piatak M Jr, Saag MS, Yang LC, Clark SJ, Kappes JC, Luk KC, et al - High levels of HIV-1 in plasma during all stages of infection determined by competitive PCR. Science 1993; 259: 1749-54.
3. Bangsberg DR, Deeks SG - Is average adherence to HIV antiretroviral therapy enough? J Gen Intern Med 2002; 17: 812-3.
4. Paterson DL, Swindells S, Mohr J - Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med 2000; 133: 21-30.
5. Griffin GE, Sissons JGP, Chiodini PL, Mitchell DM - Diseases due to infection. In: Haslett O, Chilvers ER, Hunter JAA, Boon NA, editors. Davidson's Principles and Practice of Medicine. Edinburgh: Churchill Livingstone, 1999: 87-107.
6. Jacobo-Molina A, Ding J, Nanni RG, Clark AD Jr, Lu X, Tantillo C, et al - Crystal structure of human immunodeficiency virus type 1 reverse transcriptase complexed with double-stranded DNA at 3.0 Å resolution shows bent DNA. Proc Natl Acad Sci U S A 1993; 90: 6320-4. (Pubitemid 23191507)
7. Fischl MA, Richman DD, Grieco MH, Gottlieb MS, Volberding PA, Laskin OL, et al - The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex: a double-blind placebo-controlled trial. N Engl J Med 1987; 317: 185-91.
8. Fischl MA, Richman DD, Hansen N, Collier AC, Carey JT, Para MF, et al - The safety and efficacy of zidovudine (AZT) in the treatment of subjects with mildly symptomatic human immunodeficiency virus type 1 (HIV) infection: a double-blind, placebo-controlled trial. The AIDS Clinical Trials Group. Ann Intern Med 1990; 112: 727-32.
9. Concorde Coordinating Committee - Cocorde: MRC/ANRS randomised double-blind controlled trial of immediate and deferred zidovudine in symptom-free HIV infection. Lancet 1994; 343: 871-81.
10. Kahn JO, Lagakos SW, Richman DD, Cross A, Pettincelli C, Liou SH, et al - A controlled trial comparing continued zidovudine with didanosine in human immunodeficiency virus infection. the NIAID AIDS Clinical Trials Group. N Engl J Med 1992; 327: 581-7.
11. Ding J, Das K, Tantillo C, Zhang W, Clark AD Jr, Jessen S, et al - Structure of HIV-1 reverse transcriptase in a complex with the non - nucleoside inhibitor alpha-APA R 95845 at 2.8 A° resolution. Structure 1995; 3: 365-9.
12. Conway B - Intial therapy with protease inhibitor - sparing regimens: evaluation of nevirapine and delavirdine. Clin Infect Dis 2000; 30: S 130-4.
13. Guay LA, Musoke P, Fleming T - Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial. Lancet 1999; 354: 795-802. (Pubitemid 29415583)
14. Connor EM, Sperling RS, Gelber R, Kiselev P, Scott G, O'Sullivan MJ, et al - Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N Engl J Med 1994; 331: 1173-80.
15. Olmsted RA, Slade DE, Kopta LA, Poppe SM, Poel TJ, Newport SW, et al - (Alkylamino) piperidinebis(heteroaryl) piperizine analogs are potent, broad-spectrum nonnucleoside reversetranscriptase inhibitors of drug resistant isolates of human immunodeficiency virus type 1 (HIV-1) and select for drug-resistant variants of HIV-1 III B with reduced replication phenotypes. J Virol 1996; 70: 3698-705.
16. Pauwels R, Andries K, Debyser Z, Van Daele P, Schols D, Stoffels P, et al - Potent and highly selective human immunodeficiency virus type 1 (HIV-I) inhibitition by a series of alpha-anilinophenylacetamide derivatives targeted at HIV-I reverse transcriptase. Proc Natl Acad Sci U S A 1993; 90: 1711-5.
17. Baba M, Tanaka H, De Clercq E, Pauwels R, Balzarini J, Schols D, et al - Highly specific inhibition of human immunodeficiency virus type 1 by a novel series 6 - substituted acyclouridine derivative. Biochem Biophys Res Commun 1989; 165: 1375-81. (Pubitemid 20029862)
18. Balzarini J, Brouwer WG, Felauer EE, Dr Clercq E, Karlsson A - Activity of various thiocarboxanilide derivatives against wild-type and several mutant human Immunodeficiency virus type 1 strains. Antiviral Res 1995; 27: 219-36.
19. Buckheit RW, Hollingshead M, Stinson S - Efficacy pharmacokinetics, and in vivo antiviral activity of UC781, a highly potent, orally bioavailable nonnucleoside reverse transcriptase inhibitor of HIV type 1. AIDS Res Hum Retrovirus 1997; 13: 789-96.
20. Flexner C - HIV-protease inhibitors. N Engl J Med 1998; 338: 1281-92.
21. Moyle G - Study of protease inhibitor combination in Europe (SPICE) saquinavir soft gelatin capsule (SQV-SGC) plus nelfinavir (NFV) in HIV - infected Individuals [abstract 12222]. Program and abstracts of the 12th World AIDS Conference (Geneva). Geneva: Marathon Multimedia, 1998.
22. Albrecht M, Katzenstein D, Bosch R, Liou S, Hammer S - ACTG 364: virologic efficacy of nelfinavir (NFV) and/or efaviren (EFV) in combination with new nucleoside analogues in nucleoslde-experienced sujects [abstract 12203]. Program and abstracts of the 12th World AIDS Conference (Geneva). Geneva: Marathon Multimedia, 1998.
23. Stewart K, Park C, Nienaber V - Molecular modeling and x-ray crystallographic studies of ritonavir, ATB - 378, and their analogues bound to protease [abstract 464]. Program and abstracts of the 4th Conference on Retroviruses and Opportunistic Infection (Washington, DC). Alexandria VA: Foundation for Retrovirology and Human Health, 1997.
24. Poppe SM, Slade DE, Chong KT - Antiviral activity of the dihydropyrone PNU - 140690, a new nonpeptidic human immunodeficiency virus protease inhibitor. Antimicrob Agents Chemother 1997; 41: 1058-63.
25. Viraben R, Aquilina C - Indinavir-associated lipodystrophy. AIDS 1998; 12: F37-9.
26. BHIVA - British HIV Association (BHIVA) Guidelines for the treatment of HIV-infected adults with antiretroviral therapy. HIV Med 2000; 1: 76-101.
27. Mellors J, Munoz AM, Glorgi JV - Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV01 infection. Ann Intern Med 1997; 126: 946-54. (Pubitemid 27255797)
28. Gulick RM, Mellors JW, Havlir D - Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Wed 1997; 337: 734-9.
29. Carpenter CCJ, Fischl MA, Hammer SM - Antiviral therapy for HIV infection in 1997: updated recommendations of the International AIDS Society - USA Panel. JAMA 1997; 277: 1962-9.
30. Schrager LK, D'Souza MP - Cellular and anatomical reservoirs of HIV-1 in patients receiving potent antiretroviral combination therapy. JAMA 1998; 280: 67-71.
31. Price RW - Neurological complications of HIV infection. Lancet 1996; 348: 445-52.
32. Foudraine NA, Hoetelmans RM, Lange JM - Cerebrospinal fluid HIV-1 RNA and drug concentrations after treatment with lamivudine plus zidovudine or stavudine. Lancet 1998; 351: 1547-51.
33. Stahle L, Martin C, Svensson JO - Indinavir in cerebrospinal fluid of HIV-1-infected patients. Lancet 1997; 350: 1823.
34. Deeks SG - Determinants of virological response to antiretroviral therapy: implications for long-term strategies. Clin Infect Dis 2000; 30: S 177-84.
35. Bangsberg DR, Hecht FM, Chartebois ED - Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population. AIDS 2000; 14: 357-66.
36. Mayers DL, Japour AJ, Arduino JM, Hamer SM, Reichman R, Wagner KF, et al - Dideoxynucleoside resistance emerges with prolonged zidovudine monotherapy. The RV43 Study Group. Antimicrob Agents Chemother 1994; 38: 307-14.
37. St Clair MH, Martin JL, Tudor-Williams G - Resistance to didanosine and sensitivity to zidovudine induced by a mutation in HIV-1 reverse transcriptase. Science 1991; 253: 1557-9.
38. Shafer RW, Kozal MJ, Winters MA, Iversen AK, Katzenstein DA, Ragni MW, et al - Combination therapy with zidovudine and didanosine selects for drug-resistant human immunodeficiency virus type 1 strains with unique patterns of pol gene mutations. J Infect Dis 1994; 169: 722-9.
39. Lander BA - 3-azido-3′-deoxythymidine resistance suppressed by a mutation conferring human immunodeficiency virus type 1 resistance to non - nucleoside reverse transcriptase inhibitors. Antimicrob Agents Chemother 1992; 36: 2664-9.
40. 3: AIDS Clinical Trials Group Protocol 208. J Infect Dis 1995; 172: 1379-83.
41. O'Brien WA - Resistance against reverse transcriptase inhibitors. Clin Infect Dis 2000; 30: S185-92.
42. Arora B - Retroviridae. In: Arora DR, editor. Textbook of Microbiology. 2nd ed. Delhi: CBS Publishers and Distributors, 2003; 555-70.
43. Zhang L, Ramratnam B, Tenner-racz K - Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy. N Engl J Med 1999; 27: 1605-13. (Pubitemid 29249429)